Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe).


Journal

Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310

Informations de publication

Date de publication:
01 2021
Historique:
received: 21 09 2020
revised: 14 10 2020
accepted: 23 10 2020
pubmed: 19 11 2020
medline: 9 2 2021
entrez: 18 11 2020
Statut: ppublish

Résumé

The impact of the COVID-19 pandemic on European gynaecological cancer patients under active treatment or follow-up has not been documented. We sought to capture the patient perceptions of the COVID-19 implications and the worldwide imposed treatment modifications. A patient survey was conducted in 16 European countries, using a new COVID-19-related questionnaire, developed by ENGAGe and the Hospital Anxiety & Depression Scale questionnaire (HADS). The survey was promoted by national patient advocacy groups and charitable organisations. We collected 1388 forms; 592 online and 796 hard-copy (May, 2020). We excluded 137 due to missing data. Median patients' age was 55 years (range: 18-89), 54.7% had ovarian cancer and 15.5% were preoperative. Even though 73.2% of patients named cancer as a risk factor for COVID-19, only 17.5% were more afraid of COVID-19 than their cancer condition, with advanced age (>70 years) as the only significant risk factor for that. Overall, 71% were concerned about cancer progression if their treatment/follow-up was cancelled/postponed. Most patients (64%) had their care continued as planned, but 72.3% (n = 892) said that they received no information around overall COVID-19 infection rates of patients and staff, testing or measures taken in their treating hospital. Mean HADS Anxiety and Depression Scores were 8.8 (range: 5.3-12) and 8.1 (range: 3.8-13.4), respectively. Multivariate analysis identified high HADS-depression scores, having experienced modifications of care due to the pandemic and concern about not being able to visit their doctor as independent predictors of patients' anxiety. Gynaecological cancer patients expressed significant anxiety about progression of their disease due to modifications of care related to the COVID-19 pandemic and wished to pursue their treatment as planned despite the associated risks. Healthcare professionals should take this into consideration when making decisions that impact patients care in times of crisis and to develop initiatives to improve patients' communication and education.

Sections du résumé

BACKGROUND
The impact of the COVID-19 pandemic on European gynaecological cancer patients under active treatment or follow-up has not been documented. We sought to capture the patient perceptions of the COVID-19 implications and the worldwide imposed treatment modifications.
METHODS
A patient survey was conducted in 16 European countries, using a new COVID-19-related questionnaire, developed by ENGAGe and the Hospital Anxiety & Depression Scale questionnaire (HADS). The survey was promoted by national patient advocacy groups and charitable organisations.
FINDINGS
We collected 1388 forms; 592 online and 796 hard-copy (May, 2020). We excluded 137 due to missing data. Median patients' age was 55 years (range: 18-89), 54.7% had ovarian cancer and 15.5% were preoperative. Even though 73.2% of patients named cancer as a risk factor for COVID-19, only 17.5% were more afraid of COVID-19 than their cancer condition, with advanced age (>70 years) as the only significant risk factor for that. Overall, 71% were concerned about cancer progression if their treatment/follow-up was cancelled/postponed. Most patients (64%) had their care continued as planned, but 72.3% (n = 892) said that they received no information around overall COVID-19 infection rates of patients and staff, testing or measures taken in their treating hospital. Mean HADS Anxiety and Depression Scores were 8.8 (range: 5.3-12) and 8.1 (range: 3.8-13.4), respectively. Multivariate analysis identified high HADS-depression scores, having experienced modifications of care due to the pandemic and concern about not being able to visit their doctor as independent predictors of patients' anxiety.
INTERPRETATION
Gynaecological cancer patients expressed significant anxiety about progression of their disease due to modifications of care related to the COVID-19 pandemic and wished to pursue their treatment as planned despite the associated risks. Healthcare professionals should take this into consideration when making decisions that impact patients care in times of crisis and to develop initiatives to improve patients' communication and education.

Identifiants

pubmed: 33205595
doi: 10.1002/cam4.3605
pmc: PMC7753798
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

208-219

Informations de copyright

© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Références

Ann Oncol. 2020 Aug;31(8):1065-1074
pubmed: 32442581
Lancet. 2020 Jul 4;396(10243):27-38
pubmed: 32479829
Front Psychol. 2020 Aug 24;11:2033
pubmed: 32982846
J Gynecol Oncol. 2020 Jul;31(4):e68
pubmed: 32458596
J Visc Surg. 2020 Jun;157(3S1):S25-S31
pubmed: 32387058
BMJ. 2017 Jan 25;356:j108
pubmed: 28122812
J Geriatr Oncol. 2020 Sep;11(7):1175-1181
pubmed: 32402764
Br J Surg. 2020 Oct;107(11):1440-1449
pubmed: 32395848
Int J Gynecol Cancer. 2020 May;30(5):561-563
pubmed: 32221023
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Target Oncol. 2020 Jun;15(3):249-259
pubmed: 32445083
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
Health Qual Life Outcomes. 2003 Aug 01;1:29
pubmed: 12914662
ESMO Open. 2020 May;5(Suppl 3):
pubmed: 32457036
Int J Gynecol Cancer. 2010 Jan;20(1):34-40
pubmed: 20130501

Auteurs

Murat Gultekin (M)

Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe University, Ankara, Turkey.
European Society of Gynaecological Oncoloy (ESGO, European Network of Gynaecological Cancers Advocacy Groups (ENGAGe) Executive Group, Prague, Czech Republic.

Sertac Ak (S)

Stress Assesment and Research Center (STAR, Hacettepe University, Ankara, Turkey.
Faculty of Medicine, Department of Psychiatry, Hacettepe University, Ankara, Turkey.

Ali Ayhan (A)

Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Baskent University, Ankara, Turkey.

Aleksandra Strojna (A)

Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.

Andrei Pletnev (A)

Department of Gynecologic Oncology, N.N. Alexandrov National Cancer Center of Belarus, Minsk, Belarus.

Anna Fagotti (A)

Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.

Anna Myriam Perrone (AM)

Sant Orsola-Malpighi Hospital, Bologna, Italy.

B Emre Erzeneoglu (BE)

Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe University, Ankara, Turkey.

B Esat Temiz (BE)

Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe University, Ankara, Turkey.

Birthe Lemley (B)

European Society of Gynaecological Oncoloy (ESGO, European Network of Gynaecological Cancers Advocacy Groups (ENGAGe) Executive Group, Prague, Czech Republic.
KIU - Patient Organisation for Women with Gynaecological Cancer, Copenhagen, Denmark.

Burcu Soyak (B)

Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe University, Ankara, Turkey.

Cathy Hughes (C)

Ovacome - Ovarian Cancer Support Charity, London, UK.
Department of Gynecology, Imperial College London, NHS Trust London, London, UK.

David Cibula (D)

Department of Obstetrics and Gynecology, Gynecologic Oncology Center, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Dimitrios Haidopoulos (D)

Department of Obstetrics and Gynecology, Alexandra Hospital, University of Athens, Athens, Greece.

Donal Brennan (D)

Department of Gynaecological Oncology, University College Dublin (UCD) School of Medicine, Catherine McAuley Research Centre, Mater University Hospital, Dublin, Ireland.

Edoardo Cola (E)

Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.

Elzbieta van der Steen-Banasik (E)

Radiotherapy Institute, Arnhem, The Netherlands.

Esra Urkmez (E)

European Society of Gynaecological Oncoloy (ESGO, European Network of Gynaecological Cancers Advocacy Groups (ENGAGe) Executive Group, Prague, Czech Republic.
Dance With Cancer Society, Ankara, Turkey.

Huseyin Akilli (H)

Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Baskent University, Ankara, Turkey.

Ignacio Zapardiel (I)

Gynecologic Oncology Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain.

Icó Tóth (I)

European Society of Gynaecological Oncoloy (ESGO, European Network of Gynaecological Cancers Advocacy Groups (ENGAGe) Executive Group, Prague, Czech Republic.
Mallow Flower Foundation, Budapest, Hungary.

Jalid Sehouli (J)

Department of Gynecology with Center for Oncological Surgery, Charité-University Hospital, Berlin, Germany.

Kamil Zalewski (K)

European Society of Gynaecological Oncoloy (ESGO, European Network of Gynaecological Cancers Advocacy Groups (ENGAGe) Executive Group, Prague, Czech Republic.
Department of Gynecological Oncology, Hollycross Cancer Center, Kielce, Poland.
Department of Molecular and Translational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Department of Gynaecological Oncology, Barts Health NHS Trust, London, UK.

Kiarash Bahremand (K)

Department of Gynaecology, National Institute of Oncology, Budapest, Hungary.

Luis Chiva (L)

Clinica Universidad de Navarra, Madrid, Spain.

Mansoor Raza Mirza (MR)

Department of Oncology, The Finsen Centre, Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark.

Maria Papageorgiou (M)

European Society of Gynaecological Oncoloy (ESGO, European Network of Gynaecological Cancers Advocacy Groups (ENGAGe) Executive Group, Prague, Czech Republic.
K.E.F.I. Cancer Society, Athens, Greece.

Novak Zoltan (N)

Department of Gynaecology, National Institute of Oncology, Budapest, Hungary.

Petra Adámková (P)

European Society of Gynaecological Oncoloy (ESGO, European Network of Gynaecological Cancers Advocacy Groups (ENGAGe) Executive Group, Prague, Czech Republic.
Onko Unie Cancer Society, Prague, Czech Republic.

Philippe Morice (P)

Department of Surgery, Institute Gustave Roussy, Villejuif, France.

Sonia Garrido-Mallach (S)

Gynecologic Oncology Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain.

Utku Akgor (U)

Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe University, Ankara, Turkey.

Vasilis Theodoulidis (V)

Department of Obstetrics and Gynecology, Alexandra Hospital, University of Athens, Athens, Greece.

Zafer Arik (Z)

Faculty of Medicine, Department of Medical Oncology, Hacettepe University, Ankara, Turkey.

Karina D Steffensen (KD)

European Society of Gynaecological Oncoloy (ESGO, European Network of Gynaecological Cancers Advocacy Groups (ENGAGe) Executive Group, Prague, Czech Republic.
Department of Oncology, Lillebaelt Hospital-University Hospital of Southern Denmark, Vejle, Denmark.
Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
Center for Shared Decision Making, Lillebaelt Hospital-University Hospital of Southern Denmark, Vejle, Denmark.

Christina Fotopoulou (C)

Department of Gynecology, Imperial College London, NHS Trust London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH